Download PDF
Nuklearmedizin 1984; 23(03): 127-129
DOI: 10.1055/s-0038-1624206
Originalarbeiten – Original Articles
Schattauer GmbH

Uptake of Main Fractions of Labelled Bleomycin by Solid Ehrlich Ascites Tumours in Mice[*]

Speicherung der Hauptfraktionen des markierten Bleomycins durch solide Ehrlich-Aszites-Tumore bei Mäusen
M. Rembelska
1   From the Department of Nuclear Medicine and the Department of Pathological Anatomy, Medical Academy, Lόdź, Poland
,
J. Liniecki
1   From the Department of Nuclear Medicine and the Department of Pathological Anatomy, Medical Academy, Lόdź, Poland
,
B. Koniarek
1   From the Department of Nuclear Medicine and the Department of Pathological Anatomy, Medical Academy, Lόdź, Poland
,
Z. Krawczyk
1   From the Department of Nuclear Medicine and the Department of Pathological Anatomy, Medical Academy, Lόdź, Poland
› Author AffiliationsThe authors express their appreciation of the help of Dr. E. Grzelińska in the preparation of A2, B2 and DM A2 fraction of bleomycin. The technical assistance of Mr. Adam Palczewski is gratefully acknowledged.
Further Information

Publication History

Received: 20 December 1983

Publication Date:
10 January 2018 (online)

    Permissions and Reprints

Summary

Concentrations were studied of 58Co in the solid Ehrlich ascites tumour, blood, muscle and bone of male Swiss mice administered as complexed with total bleomycin commercially available and its isolated fractions A2, B2, demethyl A2, A1, A5, B4 and bleomycinic acid. The tumour/ non-tumour ratios were determined 24 hrs after injection of the complexes. The ratios for fraction A2, B2 and total bleomycin were very close to each other. The remaining fractions showed lower values of the ratios. These results suggest that it is unlikely that any of the fractions studied are superior to total labelled bleomycin with respect to tumour scintigraphy.

Zusammenfassung

Es wurden die Konzentrationen in soliden Ehrlich-Aszites-Tumoren, Blut, Muskeln und Knochen männlicher Swiss-Mäuse von 58Co, verabreicht in Form von Komplexen mit dem kommerziell erhältlichen Bleomycin und seinen Fraktionen A2, B2, Demethyl-A2, A1, A5, B4 und Bleomycinsäure, gemessen. Das Verhältnis Tumor/Nicht-Tumor wurde 24 Std. nach Injektion der Komplexe ins Gewebe berechnet. Die Verhältnisse für die Fraktionen A2 und B2 und für das gesamte Bleomycingemisch waren einander sehr ähnlich; dagegen zeigten die restlichen, untersuchten Fraktionen wesentlich niedrigere Werte. Diese Ergebnisse lassen annehmen, daß eine Überlegenheit irgendeiner der untersuchten Fraktionen gegenüber dem Gesamtbleomycin in bezug auf die Tumorszintigraphie unwahrscheinlich ist.

* The study was performed under the research agreement no 0310 with the National Oncological Program PR-6


** Their kindness is most gratefully acknowledged.


 
  • 1 Bier J.von, Benders B. 57Co- Bleomycinkinetik nach lokaler und systemischer Applikation. Dtsch. Zahnärztl. Z. 1980; 35: 9-8.
    Google Scholar
  • 2 Kakinuma J., Kagiyama R. Chemical properties and tumor affinity of separated isomers of cobalt-bleomycin. Eur. J. nucl. Med. 1980; 05: 159-63.
    CrossrefPubMedGoogle Scholar
  • 3 Lightbown J. W., Gutteridge J. M. The international reference preparation of bleomycin. J. biol. Stand. 1981; 09: 253-63.
    CrossrefPubMedGoogle Scholar
  • 4 Liniecki J., Rembelska M., Koniarek B. Uptake of labelled tallysomycin by solid Ehrlich ascites tumours in mice. Nucl. Med. 1983; 22: 159-61.
    Google Scholar
  • 5 Van de Poll M., Rasker A. Labelling of bleomycin with cobalt-57, indium-111, technetium-99m, mercury-197, lead-203 and copper-67. Nucl. Med. 1976; 15: 86-90.
    Google Scholar
  • 6 Raban P., Brousil J. Chemical and biological properties of bleomycin labelled with 57Co. Eur. J. nucl. Med. 1979; 04: 191-7.
    CrossrefPubMedGoogle Scholar
  • 7 Rembelska M., Liniecki J. 51Crbleomycin, a new oncophilic radiopharmaceutical. I. Activity concentrations in transplantable tumours and organ-tissues of mice. Nucl. Med. 1982; 21: 62-7.
    Google Scholar
  • 8 Renault H., Wicart et J. La chelation de divers cations radioactifs par certains polypeptides utilisée comme méthode de marquage. Application à la bléomycine. C. R. Acad. Sei. Paris: 1971. 237: 2013-5.
    Google Scholar
  • 9 Rzeszotarski W., Eckelman W. Reversed-phase high performance liquid chromatography of bleomycin. J. Chromat. 1976; 124: 88-91.
    CrossrefPubMedGoogle Scholar
  • 10 Sakai T., Riordan J. Improved method for the purification of bleomycins. J. Chromat. 1979; 178: 302-6.
    CrossrefGoogle Scholar
  • 11 Shiu G., Goehl T. High-performance paired-ion liquid chromatographic determination of bleomycin A2 in urine. J. Chromat. 1980; 181: 127-31.
    CrossrefPubMedGoogle Scholar
  • 12 Shute D., Toeg D. Rapid column separation of bleomycins. Med. Lab. Sei. 1981; 38: 115-6.
    Google Scholar
  • 13 Umezawa H., Suhare Y. Purification of bleomycin. J. Antibiot. 1966; 19: 210-5.
    Google Scholar
  • 14 Umezawa H. Chemistry and mechanism of action of bleomycin. Antib. Neop. Fed. Proc. 1974; 33: 229-302.
    Google Scholar
  • 15 Vos C. M., Westera G. Different forms of the cobalt-bleomycin A2 complex. J. inorg. Biochem. 1980; 12: 45-55.
    CrossrefGoogle Scholar
  • 16 Vos C. M., Westera G. A13C nmr and esr study on the structure of the different forms of the cobalt-bleomycin A2 complex. J. inorg. Biochem. 1980; 13: 165-77.
    CrossrefGoogle Scholar
  • 17 Vos C. M., Westera G. Three different cobalt complexes of bleomycin A2, B2 and pepleomycin. J. inorg. Biochem. 1981; 15: 253-60.
    CrossrefGoogle Scholar